Children's Mercy Kansas City SHARE @ Children's Mercy

Clinical Critically Appraised Topics

Critically Appraised Topics

10-2021

Skin Soft Tissue Infection: Antibiotics for Abscesses

Children's Mercy Kansas City

Let us know how access to this publication benefits you

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/clinical-criticallyappraised-topics

Part of the Pediatrics Commons

Children's Mercy KANSAS CITY

Office of Evidence Based Practice (EBP) – Critically Appraised Topic (CAT): Skin and Soft Tissue Infection (SSTI) Abscess Antibiotic Use

Specific Care Question: In pediatric patients with suspected Skin and Soft Tissue Infection (SSTI), should antibiotics be prescribed after the abscess is drained versus no antibiotics for the outcomes of cured at follow-up and rate of recurrence?

Recommendations from the Skin and Soft Tissue Infection CPG Team *A conditional recommendation is made for the use of antibiotics for abscesses, based on the GRADE Evidence to Decision instrument the Summary of Findings Table. The overall certainty in the evidence is low to very low. In pediatric patients, the use of antibiotics following incision and drainage was favorable for cure rate versus placebo. There is little evidence for or against antibiotics following incision and drainage for abscesses <2cm. (see Summary by Outcome for substantiation of recommendations).*

The SSTI CPG Subcommittee discussed additional considerations using the GRADE Evidence to Decision instrument^a found in the appendix to recommend antibiotic therapy for abscess following incision and drainage at Children's Mercy based on feasibility, value, and compliance for all stakeholders.

Literature Summary Background

Skin and soft tissue infection is a common presentation in pediatric emergency departments and ambulatory settings, of which almost half are abscesses (Gottlieb & Peksa, 2018; Taira et al., 2009). Standard clinical treatment for abscesses includes incision and drainage, but the utility of antibiotics for simple abscesses remains unclear (Singer & Talan, 2014). The Infectious Diseases Society of America recommends that incision and drainage is likely adequate for simple abscess (Stevens et al., 2014). A recent meta-analysis (Gottlieb & Peksa, 2018) of adults and pediatric patients found that systemic antibiotics for abscesses after incision and drainage increased clinical cure rates. This contrasts with a previous meta-analysis (Fahimi et al., 2015) of adults and pediatric patients to answer the specific care question on the topic.

Study characteristics. The search for suitable studies was completed on August 31, 2021. A. Nedved, MD and E. Scott, DO reviewed the 147 titles and/or abstracts found in the search and identified^b one guideline and six single studies believed to answer the question. After an in-depth review of the guideline^d and the single studies^c, four answered the question(s). Two systematic reviews (SR) (Fahimi et al., 2015; Gottlieb et al., 2019) were identified in the search. Both SRs included both adults and pediatric patients. Only the pediatric studies from the SRs were included in the current review.

Summary by Outcome

Cure Rate 7-10 days for Children, Trimethoprim / Sulfamethoxazole (TMP-SMX) versus Placebo

Two studies (Daum et al., 2017; Duong et al., 2010) measured cure rate at 7-10 days, (n = 329). For the outcome of cure rate at 7—10 days, the OR = 1.97, 95% CI [1.04, 3.73], p = .04, indicated the intervention of TMP-SMX was favorable to the comparator of placebo (see Figure 3 & Table 2). The use of TMP-SMX would result in a cure rate of 6 to 133 more patients per 1000.

Certainty Of The Evidence For Cure Rate at 7-10 days for Children. The certainty of the body of evidence was low. The body of evidence was assessed to have no serious inconsistency, no serious indirectness, but was assessed to have serious risk of bias and serious imprecision. Risk of bias was serious as Duong et al. (2010) did not reach power and medication compliance was only 66%. Imprecision was serious due to the low number of events and participants (n = 329).

Cure Rate 7-14 days for Children and Adults, TMP-SMX versus Placebo

Three studies (Daum et al., 2017; Duong et al., 2010; Talan et al., 2016) measured cure rate at 7-14 days, (n = 1576). For the outcome of cure rate at 7-14 days, the OR = 1.55, 95% CI [1.22, 1.97], p = .0005, indicated the intervention of TMP-SMX was favorable to the comparator of placebo (see Figure 3 & Table 2). The use of TMP-SMX would result in a cure rate of 34 to 105 more patients per 1000.

Certainty Of The Evidence For Cure Rate at 7-14 days for Children and Adults. The certainty of the body of evidence was low. The body of evidence was assessed to have no serious inconsistency and no serious imprecision, but was assessed to have serious risk of bias and serious indirectness. Risk of bias was serious due to potential selection bias (Talan et al., 2016). This study made up 86% of the final weight of the metaanalysis results. Indirectness was serious due to Talan et al. (2016) included both adults and children.

Recurrence at 3 months for Children, TMP-SMX versus Placebo for Children

One studies (Duong et al., 2010) measured recurrence at 3 months, (n = 98). For the outcome of recurrence at 3 months, the OR = 0.97, 95% CI [0.40, 2.34], p = .95, indicated the intervention of TMP-SMX was no different to the comparator of placebo (see Figure 5 & Table 2).

Certainty Of The Evidence For Cure Rate at 7-10 days for Children. The certainty of the body of evidence was. The body of evidence was assessed to have no serious inconsistency, no serious indirectness, but was assessed to have serious risk of bias and serious imprecision. Risk of bias was serious due to Duong et al. (2010) not recruit enough study participants to detect significance and the medication compliance of the subjects was only 66%. Imprecision was serious due to the low number of events and participants (n = 98).

Adverse Events for Children, TMP-SMX versus Placebo

Two studies (Daum et al., 2017; Duong et al., 2010) measured adverse events, (n = 672). For the outcome of adverse events, the OR = 0.73, 95% CI [0.47, 1.15], p = .18, indicated the intervention of TMP-SMX was no different to the comparator of placebo (see Figure 4 & Table 2).

Certainty Of The Evidence For Adverse Events for Children. The certainty of the body of evidence was. The body of evidence was assessed to have no serious inconsistency, no serious indirectness, but was assessed to have serious risk of bias and serious imprecision. Risk of bias was serious due to Duong et al. (2010) not recruit enough study participants to detect significance and the medication compliance of the subjects was only 66%. Imprecision was serious due to the low number of events (n = 186).

Adverse Events for Children and Adults, TMP-SMX versus Placebo

Three studies (Daum et al., 2017; Duong et al., 2010; Talan et al., 2016) measured cure rate at 7-14 days, (n = 1709). For the outcome of adverse events, the OR = 0.89, 95% CI [0.59, 1.35], p = .59, indicated the intervention of TMP-SMX was no different to the comparator of placebo (see Figure 4 & Table 2).

Certainty Of The Evidence For Adverse Events for Children and Adults. The certainty of the body of evidence was very. The body of evidence was assessed to have no serious imprecision, but was assessed to have serious risk of bias, serious inconsistency, and serious indirectness. Risk of bias was serious due to potential selection bias of (Talan et al., 2016). This study made up 86% of the final weight of the meta-analysis results. Inconsistency was serious due to each study measuring adverse events differently and moderate heterogeneity based on I² of 77%. Indirectness was judged to be serious due to the inclusion of both adults and children (Talan et al. (2016).

Cure Rate 7-10 days for Children, Clindamycin versus Placebo

One study (Daum et al., 2017) measured cure rate at 7-10 days, (n = 190). For the outcome of cure rate at 7-10 days, the OR = 1.97, 95% CI [1.04, 3.73], p = .04, indicated the intervention of clindamycin was favorable to the comparator of placebo (see Figure 6 & Table 3). The use of clindamycin would result in a cure rate of 106 to 261 more patients per 1000.

Certainty Of The Evidence For Cure Rate at 7-10 days for Children. The certainty of the body of evidence was low. The body of evidence was assessed to not have serious risk of bias, nor serious inconsistency, or serious indirectness, but very serious imprecision. Imprecision was very serious due to the low number of events and participants (n = 190).

Adverse Events for Children, Clindamycin versus Placebo

One study (Daum et al., 2017) measured adverse events, (n = 190). For the outcome of adverse events, the OR = 3.76, 95% CI [1.74, 8.11], p = .005, indicated the intervention of clindamycin was not favorable to the placebo comparator (see Figure 7 & Table 3). The use of clindamycin would result in a 23 to 184 more adverse events per 1000 patients.

Certainty Of The Evidence For Cure Rate at 7-10 days for Children. The certainty of the body of evidence was. The body of evidence was assessed to not have serious risk of bias, nor serious inconsistency, or serious indirectness, but had very serious imprecision. Imprecision was very serious due low number of events and participants (n = 190).



Recurrence at 1 year for Children, Antibiotics versus No-antibiotics

One study (Hogan et al., 2018) measured recurrence at 1 year, (n = 383). For the outcome of recurrence at 1 year, the OR = 0.37, 95% CI [0.17, 0.84], p = .02, indicated the intervention of antibiotics (clindamycin, TMP-SMX, vancomycin) was favorable to the comparator of no-antibiotics (see Figure 8 & Table 4).

Certainty Of The Evidence For Recurrence at 1 year for Children.

The certainty of the body of evidence was low. The body of evidence was assessed to have no serious inconsistency and no serious indirectness, but was assessed to have serious imprecision and serious risk of bias. Risk of bias was serious due to the low number of participants in the comparison group. Imprecision was serious due to the low number of events (n = 90).

Identification of Studies

Search Strategy and Results (see Figure 1)

("skin and soft-tissue infection*" OR "skin and soft tissue infection*" OR SSTI OR SSTIS OR "Soft Tissue Infections"[Mesh] OR "Skin Diseases,

Infectious"[Mesh] OR "skin abscess*"[tiab] OR "skin lesion*"[tiab] OR "Subcutaneous abscess*"[tiab]) AND ("Drainage"[Mesh] OR "Incision and drainage" OR "I&D" OR "incision & drainage") AND ("Treatment Outcome"[MeSH] OR "Follow-Up Studies"[Mesh] OR follow-up OR "Watchful Waiting"[Mesh] OR "Anti-Bacterial Agents"[Mesh] OR "Recurrence"[Mesh] OR antibiotic*[tiab] OR outcome*[tiab]) AND (child OR children OR pediatr* OR paediatr* OR infant OR

adolescence)

Records identified through database searching n = 147Additional records identified through other sources n = 1

Studies Included in this Review

Citation	Study Type
Daum et al. (2017)	RCT
Duong et al. (2010)	RCT
Hogan et al. (2018)	Cohort
Talan et al. (2016)	RCT

Studies Not Included in this Review with Exclusion Rationale

Citation	Reason for exclusion
Gottlieb et al. (2019)	Pediatric study in the systematic review already included
Fahimi et al. (2015)	Pediatric study in the systematic review already included

Methods Used for Appraisal and Synthesis

<u>aThe GRADEpro Guideline Development Tool (GDT)</u> is the tool used to create the Summary of Findings (SOF) table(s) for this analysis. Using the GDT, the author of this CAT rates the certainty of the evidence based on four factors: *within-study risk of bias, consistency among studies, directness of evidence,* and *precision of effect estimates*. Each factor is subjectively judged against the author's confidence of the estimated treatment effect. Confidence is assessed as not serious, serious or very serious. If the attribute of serious or very serious is assessed, the author will provide an explanation.

^bRayyan is a web-based software used for the initial screening of titles and / or abstracts for this analysis (Ouzzani, Hammady, Fedorowicz & Elmagarmid, 2017).

•Review Manager (Higgins & Green, 2011) is a Cochrane Collaborative computer program used to assess the study characteristics as well as the risk of bias and create the forest plots found in this analysis.

^dThe Appraisal of Guidelines Research and Evaluation II (AGREE II) is an international instrument used to assess the quality and reporting of clinical practice guidelines for this analysis (Brouwers et al. 2010).

^cThe Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram depicts the process in which literature is searched, screened, and eligibility criteria is applied (Moher, Liberati, Tetzlaff, & Altman, 2009).

- ^aGRADEpro GDT: GRADEpro Guideline Development Tool (2015). McMaster University, (developed by Evidence Prime, Inc.). [Software]. Available from <u>gradepro.org</u>.
- ^bOuzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016). Rayyan-a web and mobile app for systematic reviews. *Systematic Reviews*, 5(1), 210. doi:10.1186/s13643-016-0384-4
- ^cHiggins, J. P. T., & Green, S. e. (2011). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011] (Version 5.1.0 ed.): The Cochrane Collaboration, 2011.
- ^dBrouwers, M.C. et al. for the AGREE Next Steps Consortium. (2010) AGREE II: Advancing guideline development, reporting and evaluation in healthcare. *Canadian Medical Association Journal, 182*, E839-842. Retrieved from <u>https://www.agreetrust.org/wp-content/uploads/2017/12/AGREE-II-Users-Manual-and-23-item-Instrument-2009-Update-2017.pdf</u>
- ^cMoher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). *Preferred Reporting Items for Systematic Reviews and Meta-Analyses*: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 For more information, visit <u>www.prisma-statement.org</u>.

Question Originator

SSTI CPG Team

Medical Librarian Responsible for the Search Strategy

K. Swaggart, MLIS, AHIP

- EBP Team or EBP Scholar's Responsible for Analyzing the Literature
 - J. Dusin, MS, RD, LD, CPHQ

EBP Team Member Responsible for Reviewing, Synthesizing, and Developing this Document

J. Dusin, MS, RD, LD, CPHQ

AcronymExplanationAGREE IIAppraisal of Guidelines Research and Evaluation IICATCritically Appraised TopicEBPEvidence Based PracticeMRSAMethicillin-resistant S. aureusPRISMAPreferred Reporting Items for Systematic Reviews and Meta-AnalysesSSTISkin and Soft Tissue InfectionTMP-SMXTrimethoprim / Sulfamethoxazole	Acronyms Used ii	Acronyms Used in this Document							
CATCritically Appraised TopicEBPEvidence Based PracticeMRSAMethicillin-resistant S. aureusPRISMAPreferred Reporting Items for Systematic Reviews and Meta-AnalysesSSTISkin and Soft Tissue Infection	Acronym	Explanation							
EBPEvidence Based PracticeMRSAMethicillin-resistant S. aureusPRISMAPreferred Reporting Items for Systematic Reviews and Meta-AnalysesSSTISkin and Soft Tissue Infection	AGREE II	Appraisal of Guidelines Research and Evaluation II							
MRSAMethicillin-resistant S. aureusPRISMAPreferred Reporting Items for Systematic Reviews and Meta-AnalysesSSTISkin and Soft Tissue Infection	CAT	Critically Appraised Topic							
PRISMAPreferred Reporting Items for Systematic Reviews and Meta-AnalysesSSTISkin and Soft Tissue Infection	EBP	Evidence Based Practice							
SSTI Skin and Soft Tissue Infection	MRSA	Methicillin-resistant S. aureus							
	PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses							
TMP-SMX Trimethoprim / Sulfamethoxazole	SSTI	Skin and Soft Tissue Infection							
	TMP-SMX	Trimethoprim / Sulfamethoxazole							

Statistical Acronyms Used in this Document

Statistical Acronym	Explanation
CI	Confidence Interval
HR	Hazard Ratio
I^2	Heterogeneity test
M or \overline{X}	Mean
Mdn	Median
n	Number of cases in a subsample
N	Total number in sample
OR	Odds Ratio
P or p	Probability of success in a binary trial
RCT	Randomized controlled trial
SD	Standard deviation
SR	Systematic Review



Figure 1

Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA)^c






Table 1

AGREE II^d Summary for the IDSA Guideline (Stevens et al., 2014)

Domain	Percent Agreement	Percent Justification
Scope and purpose	99%	The aim of the guideline, the clinical questions posed, and target populations were identified.
Stakeholder involvement	58%	The guideline <u>did not</u> include appropriate stakeholders (such as nurses and pharmacist) nor the viewpoints if the intended user.
Rigor of development	79%	The process used to gather and synthesize the evidence, the methods to formulate the recommendations and to update the guidelines were explicitly stated.
Clarity and presentation	100%	The guideline recommendations are clear, unambiguous, and easily identified; in addition, different management options are presented.
Applicability	36%	The guideline <u>did not</u> address implementation barriers and facilitators, utilization strategies, nor resource costs associated with implementation.
Editorial independence	96%	The recommendations were not biased with competing interests.
Team's recommendation for guideline use	Yes with modifications	

Note: Four EBP Scholars completed the AGREE II on this guideline.



Figure 2

Risk of Bias Summary

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Daum 2017	•	•	•	?	•	•	•
Doung 2010	•	?	•	•		•	
Talan 2016	•	•	•	•	•	•	?



Summary of Findings Table(s)

Table 2

Summary of Findings Table^a: TMP-SMX compared to Placebo

		Cert	ainty assessm	ent			Summary of findings				
Deutisiusute				Imprecision		Overall	-	ent rates ⁄₀)	Deletive	-	ted absolute fects
Participants (studies) Follow-up	Risk of bias	Inconsistency	Indirectness		bias	certainty of evidence	With Placebo	With TMP- SMX	Relative effect (95% CI)	Risk with Placebo	Risk difference with TMP- SMX
Cure Rate 7-	14 days (Children and Ad	lults								
1576 (3 RCTs)	serious ^{a,b}	not serious	serious ^c	not serious	none	⊕⊕⊖⊖ Low	587/782 (75.1%)	652/794 (82.1%)	OR 1.55 (1.21 to 1.97)	751 per 1,000	73 more per 1,000 (from 34 more to 105 more)
Cure Rate 7-	10 days 0	Children									
329 (2 RCTs)	serious ^b	not serious	not serious	serious ^d	none	⊕⊕⊖⊖ Low	133/165 (80.6%)	145/164 (88.4%)	OR 1.97 (1.04 to 3.73)	806 per 1,000	85 more per 1,000 (from 6 more to 133 more)
Adverse Eve	nts Adult	s and Children	·								
1709 (3 RCTs)	serious ^{a,b}	serious ^e	serious ^c	not serious	none	⊕⊖⊖⊖ Very low	102/837 (12.2%)	98/872 (11.2%)	OR 0.89 (0.59 to 1.35)	122 per 1,000	12 fewer per 1,000 (from 46 fewer to 36 more)
Adverse Eve	nts Childı	ren									
672 (2 RCTs)	serious ^b	not serious	not serious	serious ^d	none	⊕⊕⊖⊖ Low	99/333 (29.7%)	88/339 (26.0%)	OR 0.73 (0.47 to 1.15)	297 per 1,000	61 fewer per 1,000 (from 131 fewer to 30 more)
Recurrence 3	3 months	Children									



		Certa	ainty assessm	Summary of findings							
98 (1 RCT)	serious ^f	not serious	not serious	serious ^d	none	⊕⊕⊖⊖ Low	15/52 (28.8%)	13/46 (28.3%)	OR 0.97 (0.40 to 2.34)	288 per 1,000	6 fewer per 1,000 (from 149 fewer to 198 more)

Explanations

a. Potential selection bias due to physicians ability to exclude patients at higher risk (Talan et al., 2016). Talan et al. (2016) study has 86% weight in metaanalysis.

b. Duong et al. (2010) not recruit enough study participants to detect significance and the medication compliance of the subjects was only 66%.

c. One study (Talan et al., 2016) included both adults and children.

d. Low number of events and subjects.

e. Adverse events measured differently in each study.

f. Study did not reach power and only a medication compliance rate of 66% (Doung et al., 2010).



Table 3

Summary of Findings Table: Clindamycin compared to Placebo

		Cert	tainty assessn	nent			Summary of findings						
Deuticinente	Diala		Indirectness	Imprecision	Publication bias	Overall certainty of evidence	-	event rates (%)	Deletive	Anticipated absolute effects			
Participants (studies) Follow-up		Inconsistency					With	With Clindamycin	Relative effect (95% CI)	Risk with Placebo	Risk difference with Clindamycin		
Cure Rate 7-	Cure Rate 7-10 days												
190 (1 RCT)	not serious	not serious	not serious	very serious ^a	none	⊕⊕⊖⊖ Low	61/89 (68.5%)	90/101 (89.1%)	OR 3.76 (1.74 to 8.11)	685 per 1,000	206 more per 1,000 (from 106 more to 261 more)		
Adverse Eve	nts		·	·							·		
523 (1 RCT)	not serious	not serious	serious ^b	very serious ^a	none	⊕⊖⊖⊖ Very low	32/257 (12.5%)	58/266 (21.8%)	OR 1.96 (1.22 to 3.14)	125 per 1,000	93 more per 1,000 (from 23 more to 184 more)		

Explanations

a. Low number of events and participants

b. Includes children and adults



Table 4

Summary of Findings Table: Antibiotics compared to No-Antibiotics

		Cert	ainty assessm		Summary of findings						
		Inconsistency				Overall certainty	Study even	Study event rates (%)		Anticipated absolute effects	
	Risk of bias		Indirectness	Imprecision	bias		With No- Antibiotics (observati onal study)	With Antibiotics		Risk with No- Antibiotics (observati onal study)	Risk difference with Antibiotics
Recurrent SS	TI at 1 y	ear									
383 (1 observational study)	seriousª	not serious	not serious	serious ^b	none	⊕⊖⊖⊖ Very low	18/28 (64.3%)	143/355 (40.3%)	OR 0.37 (0.17 to 0.84)	643 per 1,000	243 fewer per 1,000 (from 409 fewer to 41 fewer)

Explanations

a. Low number of participants in the comparison group

b. Low number of events



Meta-analysis(es) Figure 3 Comparison: TMP-SMX versus Placebo, Outcome: Cure Rate

	TMP-SMX Placebo					Odds Ratio	Odds	Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixe	d, 95% Cl	ABCDEFG
1.1.1 Cure Rate 7-10	days Chil	dren							
Daum 2017	75	91	61	89	10.5%	2.15 [1.07, 4.34]			$\bullet \bullet \bullet ? \bullet \bullet \bullet$
Doung 2010	70	73	72	76	2.8%	1.30 [0.28, 6.00]			• ? • • • • •
Subtotal (95% CI)		164		165	13.3%	1.97 [1.04, 3.73]			
Total events	145		133						
Heterogeneity: Chi ² =		•		:0%					
Test for overall effect:	Z = 2.09 ((P = 0.0	4)						
1.1.2 Cure Rate 7-14	days Chil	ldren a	nd Adults	6					
Talan 2016	507	630	454	617	86.7%	1.48 [1.13, 1.93]			$\bullet \bullet \bullet \bullet \bullet \bullet \bullet \circ \circ$
Subtotal (95% CI)		630		617	86.7%	1.48 [1.13, 1.93]		◆	
Total events	507		454						
Heterogeneity: Not ap	plicable								
Test for overall effect:	Z = 2.89 ((P = 0.0	04)						
Total (95% CI)		794		782	100.0%	1.55 [1.21, 1.97]		•	
Total events	652		587						
Heterogeneity: Chi² =	1.01, df=	2 (P =	0.60); l² =	:0%			0.2 0.5		
Test for overall effect:	Z = 3.48 ((P = 0.0)	005)					Favors TMP-SMX	
Test for subgroup diffe	erences:	Chi² = (0.66, df=	1 (P =	0.42), I ^z =	:0%	1 40010 1 140000		
Risk of bias legend									
(A) Random sequenc	e genera	tion (se	election b	ias)					
(B) Allocation conceal	ment (se	lection	bias)						
(C) Blinding of particip									
(D) Blinding of outcom			-	n bias)					
(E) Incomplete outcon									
(F) Selective reporting	(reportin	g bias)							
(G) Other bias									



Figure 4


Comparison: TMP-SMX versus Placebo, Outcome: Adverse Events

	TMP-SMX Placebo					Odds Ratio	Odds Ratio	Risk of Bias				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% CI	ABCDEFG				
1.2.1 Adverse Events	Children											
Daum 2017	29	263	32	257	61.5%	0.87 [0.51, 1.49]		$\bullet \bullet \bullet ? \bullet \bullet \bullet$				
Doung 2010 Subtotal (95% CI)	59	76 339	67	76 333	32.0% <mark>93.5%</mark>	0.47 [0.19, 1.12] 0.73 [0.47, 1.15]	•					
Total events	88		99									
Heterogeneity: Chi ² =	1.42, df=	1 (P =	0.23); l ² =	: 29%								
Test for overall effect:	Z=1.34 ((P = 0.1	8)									
1.2.2 Adverse Events	Adults a	nd Chil	dren									
Talan 2016 Subtotal (95% CI)	10	533 533	3	504 <mark>504</mark>	6.5% <mark>6.5%</mark>	3.19 [0.87, 11.67] 3.19 [0.87, 11.67]	•	•••••				
Total events	10		3									
Heterogeneity: Not ap	plicable											
Test for overall effect:	Z=1.76 ((P = 0.0	8)									
Total (95% CI)		872		837	100.0%	0.89 [0.59, 1.35]	•					
Total events	98		102									
Heterogeneity: Chi ² =	•	•		: 66%			0.005 0.1 1 10 200					
Test for overall effect:		•					Favors TMP-SMX Favors Placebo					
Test for subgroup diff	erences:	Chi ² = 4	4.41, df=	1 (P =	0.04), I ² =	77.3%						
Risk of bias legend												
(A) Random sequence	-			ias)								
(B) Allocation conceal				formon	co bioc)							
	(C) Blinding of participants and personnel (performance bias) (D) Blinding of outcome assessment (detection bias)											
	(D) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrition bias)											
(F) Selective reporting	-		-									
(G) Other bias	,	,										



Figure 5

Comparison: TMP-SMX versus Placebo, Outcome: Recurrence at 3 months



(A) Random sequence generation (selection bias)

(B) Allocation concealment (selection bias)

(C) Blinding of participants and personnel (performance bias)

(D) Blinding of outcome assessment (detection bias)

(E) Incomplete outcome data (attrition bias)


(F) Selective reporting (reporting bias)

(G) Other bias



Figure 6

Comparison: Clindamycin versus Placebo, Outcome: Cure Rate 7 to 10 days



Risk of bias legend

(A) Random sequence generation (selection bias)

(B) Allocation concealment (selection bias)

(C) Blinding of participants and personnel (performance bias)

(D) Blinding of outcome assessment (detection bias)

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Other bias



Figure 7 **Comparison: Clindamycin versus Placebo, Outcome: Adverse Events** Clindamycin Placebo Odds Ratio Odds Ratio Risk of Bias Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% CI M-H, Fixed, 95% Cl ABCDEFG Daum 2017 58 266 32 257 100.0% 1.96 [1.22, 3.14] Total (95% CI) 266 257 100.0% 1.96 [1.22, 3.14] Total events 58 32 Heterogeneity: Not applicable 0.01 0.1 10 100 Test for overall effect: Z = 2.80 (P = 0.005) Favors Clindamycin Favors Placebo Risk of bias legend (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias)

(C) Blinding of participants and personnel (performance bias)

(D) Blinding of outcome assessment (detection bias)

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)


(G) Other bias



Figure 8

Comparison: Antibiotics versus No Antibiotics, Outcome: Recurrent SSTI at 1 Year

Antibiotics versus No-Antibiotics (observational study), outcome: 4.1 Recurrent SSTI at 1 year.





Characteristics of Intervention Studies **Daum et al. (2017)**

Methods	Randomized Conti	ol Tria	l						
Participants	Participants: Outpatient adults and Children May 2009 through January 2015 Setting: Urgent care clinics, emergency departments, and affiliated clinics at six sites: the University of Chicago Medical Center, Chicago; San Francisco General Hospital, San Francisco; Harbor–University of California, Los Angeles, Medical Center, Torrance; Vanderbilt University Medical Center, Nashville, Washington University, St. Louis and Morehouse School of Medicine Emory University, Atlanta								
	Randomized into s Group 1, Cl Group 2, Tl Group 3, Pl Completed Study: Group 1: n Group 2: n Group 3: n Gender, males (as Group 1: n Group 1: n Group 2: n Group 2: n Group 2: n Group 3: n	indamy MP-SM2 acebo: N = 67 = 234 = 226 = 218 define = 140 (= 152 (= 156 (<pre>/cin: n (: n = 2 n = 25 8 d by re 52.6%) 57.8%) 60.7%)</pre>	= 266 63 7 search	-	acearchere).			
					All Groups				
	Native American or Alaskan		2	1	3				
	Asian	8	4	2	14				
	Hawaiin or Pacific Islander	2	4	2	8				
		165	152	167	484				
	Black or African American								
	White	80	87	73	240				
		80 5	87 11	73 8	240 24				

Children's Mercy

Office of Evidence Based Practice (EBP) – Critically Appraised Topic (CAT): Skin and Soft Tissue Infection (SSTI) Abscess Antibiotic Use

	for par • Evidence • Evidence • Construction • Superficion • Infection • Human co • Oral terr • Presence • Immuno • Body-ma • Surgical • Systemic • Requirect • Lived in • cancer • Inflamm Power Analysis	6 56 39 scess (def ticipants 6 d by two o Erythem Swelling Local wa Purulent Tendern ria: al skin infe at a body or animal b perature h of system suppressive site or pros tanti-staph hospitaliza a long-tern atory disor	9 51 31 ined as a to 11 mo r more of a or indura armth drainage ess to pa ections (e. site requi ite igher than ic inflamm e therapy the weigh sthetic de hylococcal ation n care fac der treate was desig	2 59 28 circums of the foll ation g., impe in or pa g., impe in 38.5°C natory r or an in t in kilog vice infe antibac ility	age and ≤ owing sign lpation etigo) ecialized m C (or > 38. response s mmunocor grams divi ection cterial then a superior	ainable collection of pus) with a greatest diameter of 5.0 cm or less (≤3 cm 4 cm for participants 1 to 8 years of age), ns or symptoms for at least 24 hours: nanagement (e.g., perirectal, genital, or hand infection) 0°C for children 6 to 11 months of age) yndrome criteria npromising condition (e.g., diabetes or chronic renal failure), ided by the square of the height in meters) higher than 40 rapy in the previous 14 days rity trial with 80% power to detect a 10-percentage-point absolute ticipants were required (262 per group).
Interventions	 Both: After incision and drainage of the abscess and determination of the size of the abscess, participants were randomly assigned in a 1:1:1 ratio to receive placebo, clindamycin, or TMP-SMX. Participants were seen at the end of treatment (day 12), at the test-of-cure visit (7 to 10 days after the prescribed 10-day course of therapy), and at the 1-month follow-up (day 40). Group 1: Clindamycin was given as two 150-mg tablets three times daily Group 2: TMP-SMX was given as two tablets (containing 80mg of trimethoprim and 400 mg of sulfamethoxazole) twice daily plus one dose of placebo pills Group 3: Two placebo pills given three times daily 					
Outcomes	Primary outcom Clinical of Secondary out Clinical of	ne(s): ure by day come(s)	7 to 10 c			



	• 4	y outcome(s): • Adverse events* omes of interest to the CMH CPG or CAT development team				
Notes	 Ten days after therapy in the intention-to-treat population, the cure rate: Clindamycin: 221 of 266 participants [83.1%] TMP-SMX: 215 of 263 participants [81.7%] Placebo: 177 of 257 participants [68.9%], p < .001 for both comparisons New infections at 1 month of follow-up Clindamycin: 15 of 221, 6.8% TMP-SMX: 29 of 215, 13.5%, p = .03 Placebo: 22 of 177, 12.4%, p = .06 Adverse events Clindamycin: 58 of 265, 21.9% TMP-SMX: 29 of 261, 11.1% Placebo 32 of 255, 12.5% 					
Risk of bias						
Bias	-	Judgment	Support for judgment			
Random sequence gener (selection bias)	ration	Low risk	Variable-block randomization			
Allocation concealment (selection bias)			Allocation determines by independent statistics and data-coordinating center			
Blinding of participants and Low risk personnel (performance bias)		Low risk	Participants and all study staff were unaware of the study-group assignments			
Blinding of outcome Unclear risk assessment (detection bias)		Unclear risk	Staff assessing outcomes were unaware of study groups			
Incomplete outcome dat (attrition bias)	Incomplete outcome data (attrition bias)		Intention-to-Treat was used for primary outcome			
Selective reporting (repo	Selective reporting (reporting Low risk bias)		All outcomes reported			
Other bias		Low risk				



Duong et al. (2010)

Methods	Randomized Control Trial
Participants	Participants: Pediatric Patients July 2006 through February 2008 Setting: Emergency Department in Saint Louis Medical Center
	Randomized into study: $N = 161$
	• Group 1, TMP-SMX: n = 77
	• Group 2, Placebo: <i>n</i> = 85
	Completed Study: N = 149
	• Group 1: n = 73
	• Group 2: n = 76
	Gender, males (as defined by researchers):
	• Group 1: n = 28 (39%)
	• Group 2: $n = 34 (45\%)$
	Race / ethnicity or nationality (as defined by researchers):
	• Black: 128/149 (85%)
	Age, (<5 years)
	• Group 1: 40/76 (53%)
	• Group 2: 39/73 (53%)
	Inclusion Criteria:
	 Diagnostic criteria for skin abscess included the presence of all of the following features:
	 Acute onset within 1 week
	o Fluctuance,
	o Erythema
	 Induration
	 Tenderness, with or without purulent drainage.
	Exclusion Criteria:
	Chronic health problems
	Immunosuppressive medications
	Current antibiotic usage
	Contraindication to TMP-SMX
	 Minor or superficial skin infections
	Power Analysis: The sample size of 81 per group was calculated according to assumed treatment failure rate of
	3.3% with antibiotics, an equivalence threshold of 7% (allowing up to 10.3% failure rate with placebo), to achieve
	power of 0.80 (0.05).
Interventions	Both:
	 Ultrasonography was available, measurements were made in 2 dimensions, diameter and depth. Local anesthetic or procedural sedation was used at the discretion of the attending physician
	 The skin overlying all skin abscesses was cleansed with 10% povidone iodine solution and then incised with a
	 The skin overlying all skin abscesses was cleansed with 10% povidone logine solution and then incised with a no. 11 blade, probed for loculations, and irrigated with normal saline solution.
Date Developed: 10/28/202	

Children's Me	rcy o	office of Evidence Based Practice (EBP) – Critically Appraised Topic (CAT): Skin and Soft Tissue Infection (SSTI) Abscess Antibiotic Use		
		bscess cultures obtained immediately after surgical incision and sent for culture and antibiotic sensitivity esting. Group 1: TMP-SMX dose for mild bacterial infections (10-12 mg trimethoprim/kg/ day divided into 2 doses, with a maximum dose of 160 mg trimethoprim/dose). Group 2: The placebo consisted of a Maalox and tonic water combination that resembled the antibiotic in color, texture, and taste.		
Outcomes	• Second • • Safety •	y outcome(s): Clinical resolution or failure at 10 days* dary outcome(s) New Lesions on day 10 New lesions on day 3-months outcome(s): Adverse events* mes of interest to the CMH CPG or CAT development team		
yie • Ne dif • At		e failure rates were 5.3% ($n = 4/76$) and 4.1% ($n = 3/73$) in the placebo and antibiotic groups, respectively, ding a difference of 1.2. w lesions occurred at the 10-day follow-up: 19 on placebo (26.4%) and 9 on antibiotics (12.9%), yielding a erence of 13.5. the 3-month follow-up, 15 of 52 (28.8%) in the placebo group and 13 of 46 (28.3%) in the antibiotic group veloped new lesions. The difference was 0.5%.		
Risk of bias				
Bias	Judgment	Support for judgment		
Random sequence generation (selection bias)	Low risk	Computer randomization program		
Allocation concealment (selection bias)	Unclear risk	Not discussed		
Blinding of participants and personnel (performance bias)	Low risk	Participants and personal blinded		
Blinding of outcome assessment (detection bias)	Low risk	The patient, parents, and clinician who assessed the clinical outcome were blinded to group assignment		
Incomplete outcome data (attrition bias)	High risk	Per-protocol and study did not meet power		
Selective reporting (reporting bias)	Low risk	All outcomes reported		
Other bias	High risk	Low compliance rate of medications of 66%		



Hogan et al. (2018)

Methods	Cohort, prospectively
Participants	Participants: <21-year-old, 2008-2016
Interventions	 Both: Incision and Drainage Group 1: Received guideline-recommended empiric systemic antibiotics Clindamycin, n = 220 (57%) TMP-SMX, n = 199 (52%) Vancomycin n = 19 (5%) β-lactam n = 12 (3%) Group 2: Did not receive guideline-recommended empiric systemic antibiotics
Outcomes	Primary outcome(s): • Colonized with S. aureus at follow-up Secondary outcome(s): • Recurrent SSTI at 1 year
Notes	 Results: Antibiotics for purulent SSTI were less likely to remain colonized at follow-up sampling, adjusted hazard ratio (aHR) = 0.49; 95% CI [.30, .79]

Children's Mer	CY Office of Evidence Based Practice (EBP) – Critically Appraised Topic (CAT): Skin and Soft Tissue Infection (SSTI) Abscess Antibiotic Use
	 Antibiotics are less likely to have recurrent SSTI, aHR = 0.57, 95% CI [.34, .94] Clindamycin was more effective than TMP-SMX in eradicating S. aureus colonization (44% vs 57% remained colonized, p = .03) and preventing recurrent SSTI (31% vs 47% experienced recurrence, p = .008).
	Limitations:
	Limited number of antibiotic free patients
	 Only looked at patients with S. aureus



Talan et al. (2016)

Methods	Randomized Control Trial
Participants	Participants: Adults and children older than 12 years of age, April 2009 to April 2013
	Setting: Five US Emergency Departments
	Randomized into study: N = 1265
	• Group 1, TMP-SMX: n = 636
	• Group 2, Placebo: <i>n</i> = 629
	Completed Study: N = 1013
	• Group 1: <i>n</i> = 504
	• Group 2: n = 509
	Gender, males (as defined by researchers):
	• Group 1: n = 364 (57.8%)
	• Group 2: n = 362 (58.7%)
	Race / ethnicity or nationality (as defined by researchers):
	Not reported
	Age, Median (IQR)
	• Group 1: 35 (26-47)
	• Group 2: 35 (26-48)
	Inclusion Criteria:
	 Older than 12 years of age
	Cutaneous lesion that was suspected to be an abscess on the basis of physical examination and ultrasonography or
	examination alone
	 Purulent material on surgical exploration
	 Lesion present for less than 1 week
	At least 2.0 cm in diameter
	 Intended outpatient treatment.
	Agreed to return for reevaluation
	Exclusion Criteria:
	 Indwelling device; suspected osteomyelitis or septic arthritis; diabetic foot, decubitus, or ischemic ulcer; mammalian bite; wound with organic foreign body; infection of another organ system/site; perirectal, perineal or paronychial location; intravenous drug use within previous month and fever; underlying skin condition; long-term care residence; incarceration; immunodeficiency; creatinine clearance <50 mL/min; cardiac condition with risk of endocarditis; allergy or intolerance to trimethoprim-sulfamethoxazole; taking warfarin, phenytoin, or methotrexate; known G-6-PD or folic acid deficiency; pregnant or lactating; trimethoprim-sulfamethoxazole treatment within 24 hours; concurrent treatment with topical or systemic antibiotic; or enrolled in the study within 12 weeks.
	Power Analysis:
	Enrollment of 590 participants would provide a power of 90% to detect an absolute between-group difference of 7.5 percentage points, assuming a cure rate of 90%
Interventions	Both: Incision and drainage of abscess



LALP KANSAS CITY		Skill and Soft Tissue Infection (SST1) Abscess Antibiotic Ose		
	 Group 1: 7-day course of trimethoprim-sulfamethoxazole (four single-strength pills, each containing 80 mg of trimethoprim and 400 mg of sulfamethoxazole, twice daily) Group 2: Placebo (four pills containing microcrystalline cellulose, twice daily). 			
Outcomes	Primary outcome(s): • Clinical cure of abscess, assessed 7 to 14 days Secondary outcome(s) • Subsequent surgical drainage procedures • Skin infections at new sites Safety outcome(s): • Adverse events			
Notos	*Outcomes of	f interest to the CMH CPG or CAT development team		
Notes Risk of bias table				
Bias	Judgment	Support for judgment		
Random sequence generation (selection bias)	Low risk	Web-based randomization, assigned participants in a 1:1 ratio		
Allocation concealment (selection bias)	Low risk	Drug package identical		
Blinding of participants and personnel (performance bias)	Low risk	Participants and personnel blinded		
Blinding of outcome assessment (detection bias)	Low risk	Outcome assessors blinded		
Incomplete outcome data (attrition bias)	Low risk	Intention-to-treat, secondary outcome per-protocol		
Selective reporting (reporting bias)	Low risk	All outcomes reported		
Other bias	Unclear risk	potential selection bias due to physicians' ability to exclude patients at higher risk.		



References

Reference marked with an asterisk indicate study included in the meta-analysis.

- Daum, R. S., Miller, L. G., Immergluck, L., Fritz, S., Creech, C. B., Young, D., . . . Chambers, H. F. (2017). A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses. *N Engl J Med*, *376*(26), 2545-2555. https://doi.org/10.1056/NEJMoa1607033
- *Duong, M., Markwell, S., Peter, J., & Barenkamp, S. (2010). Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient. *Annals of emergency medicine*, *55*(5), 401-407.
- Fahimi, J., Singh, A., & Frazee, B. W. (2015). The role of adjunctive antibiotics in the treatment of skin and soft tissue abscesses: a systematic review and meta-analysis. *Cjem*, *17*(4), 420-432. https://doi.org/10.1017/cem.2014.52
- Gottlieb, M., DeMott, J. M., Hallock, M., & Peksa, G. D. (2019). Systemic Antibiotics for the Treatment of Skin and Soft Tissue Abscesses: A Systematic Review and Meta-Analysis. *Ann Emerg Med*, *73*(1), 8-16. https://doi.org/10.1016/j.annemergmed.2018.02.011
- Gottlieb, M., & Peksa, G. D. (2018). Comparison of the loop technique with incision and drainage for soft tissue abscesses: A systematic review and metaanalysis. *Am J Emerg Med*, *36*(1), 128-133. https://doi.org/10.1016/j.ajem.2017.09.007
- Hogan, P. G., Rodriguez, M., Spenner, A. M., Brenneisen, J. M., Boyle, M. G., Sullivan, M. L., & Fritz, S. A. (2018). Impact of Systemic Antibiotics on Staphylococcus aureus Colonization and Recurrent Skin Infection. *Clin Infect Dis*, 66(2), 191-197. https://doi.org/10.1093/cid/cix754
- Singer, A. J., & Talan, D. A. J. N. E. J. o. M. (2014). Management of skin abscesses in the era of methicillin-resistant Staphylococcus aureus. 370(11), 1039-1047.
- Stevens, D. L., Bisno, A. L., Chambers, H. F., Dellinger, E. P., Goldstein, E. J., Gorbach, S. L., . . . Wade, J. C. (2014). Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. *Clin Infect Dis*, *59*(2), e10-52. https://doi.org/10.1093/cid/ciu444
- Taira, B. R., Singer, A. J., Thode Jr, H. C., & Lee, C. C. J. T. A. j. o. e. m. (2009). National epidemiology of cutaneous abscesses: 1996 to 2005. 27(3), 289-292.
- Talan, D. A., Mower, W. R., Krishnadasan, A., Abrahamian, F. M., Lovecchio, F., Karras, D. J., . . . Moran, G. J. (2016). Trimethoprim-Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess. *N Engl J Med*, *374*(9), 823-832. <u>https://doi.org/10.1056/NEJMoa1507476</u>



Appendix

Problem Is the problem a priority	ı?	
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
 No Probably no Probably yes Yes Varies Don't know 	Skin and soft tissue infection is a common presentation in pediatric emergency departments and ambulatory settings, of which almost half are abscesses (Gottlieb & Peksa, 2018; Taira et al., 2009). Standard clinical treatment for abscesses includes incision and drainage, but the utility of antibiotics for simple abscesses remains unclear (Singer & Talan, 2014). The Infectious Diseases Society of America recommends that incision and drainage are likely adequate for simple abscesses (Stevens et al., 2014).	
Desirable Effects How substantial are the	desirable anticipated effects?	
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
 Trivial Small Moderate Large Varies Don't know 	 Desirable effects of giving antibiotics Clinical Cure Decreased recurrence Improvement in pain 	
Undesirable Effects How substantial are the	undesirable anticipated effects?	
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
 Large Moderate Small Trivial Varies Don't know 	 Undesirable effects of giving antibiotics Adverse Events Increase in bacterial resistance Varies by antibiotic type 	TMP-SMX and clindamycin have different side effect, but the risk of Steven Johnson Syndrome or Toxic Epidermal Necrolysis are the potential adverse events of greatest concern with TMP-SMX. Additionally, the poor palatability of clindamycin may negatively impact medication compliance.



JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
 Very low Low Moderate High No included studies 	Certainty of evidence for TMP-MPX and clindamycin following incision and drainage on clinical cure and three-month recurrence is low	

Values

Is there important uncertainty about or variability in how much people value the main outcomes?

JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
 Important uncertainty or variability Possibly important uncertainty or variability Probably no important uncertainty or variability No important uncertainty or variability No important uncertainty or variability 	Probably no important uncertainty or variability in how much people value the main outcome	

Balance of effects

Does the balance between desirable and undesirable effects favor the intervention or the comparison?

JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS			
 Favors the comparison Probably favors the comparison Does not favor either the intervention or the comparison Probably favors the intervention Favors the intervention Varies Don't know 	 Clinical cure versus all undesirable effects (adverse events) Probably favors the intervention of antibiotics 				
Resources required How large are the resource require	ements (costs)?				
JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS					



 Large costs Moderate costs Negligible costs and savings Moderate savings 	Cost is negligible	There is cost associated with antibiotics, but there are generic, inexpensive formulations of both TMP-SMX and clindamycin.
 Large savings Varies Don't know 		According to the CM standard charges for 2022, self-pay costs per unit include: Clindamycin 150mg capsule – \$7.07 Clindamycin 300mg capsule - \$10.13 Clindamycin 75mg/5ml liquid - \$2.55 TMP 40mg, SMX 200mg/5ml liquid - \$2.64 TMP 80mg, SMX 400mg tablet - \$\$7.79

Certainty of evidence of required resources

What is the certainty of the evidence of resource requirements (costs)?

JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS		
 Very low Low Moderate High No included studies 	There is certainty in the required resources			

Cost effectiveness

Does the cost-effectiveness of the intervention favor the intervention or the comparison?

JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
 Favors the comparison Probably favors the comparison Does not favor either the intervention or the comparison Probably favors the intervention Favors the intervention Varies No included studies 	Cost favors the intervention	While cost is associated with the antibiotic prescription, it is negligible compared to the cost of treatment failure (repeat clinic or ED visit, readmission, and/or repeat incision and drainage).
Equity What would be the impact on heal	th equity?	
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS

Children's Mercy	Office of Evidence Based Practice (EBP) – Critically Appraised Topic (CAT): Skin and Soft Tissue Infection (SSTI) Abscess Antibiotic Use

 Reduced Probably reduced Probably no impact Probably increased Increased Varies Don't know 	The cost of medication without insurance could impact subgroup populations. Subgroups may have less reliable transportation to a pharmacy. Subgroups may also have language or literacy barriers that impact the efficacy of prescription instructions.	Please see standard costs above.
Acceptability Is the intervention acceptable to k	ey stakeholders?	
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
 No Probably no Probably yes Yes Varies Don't know 	Families and clinicians are likely to accept the intervention.	
Feasibility Is the intervention feasible to imp	lement?	1

JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
 No Probably no Probably yes Yes Varies Don't know 	The intervention is feasible	

SUMMARY OF JUDGEMENTS

_	JUDGEMENT						
PROBLEM	No	Probably no	Probably yes	Yes		Varies	Don't know
DESIRABLE EFFECTS	Trivial	Small	Moderate	Large		Varies	Don't know
UNDESIRABLE EFFECTS	Large	Moderate	Small	Trivial		Varies	Don't know
CERTAINTY OF EVIDENCE	Very low	Low	Moderate	High			No included studies



	JUDGEMENT						
VALUES	Important uncertainty or variability	Possibly important uncertainty or variability	Probably no important uncertainty or variability	No important uncertainty or variability			
BALANCE OF EFFECTS	Favors the comparison	Probably favors the comparison	Does not favor either the intervention or the comparison	Probably favors the intervention	Favors the intervention	Varies	Don't know
RESOURCES REQUIRED	Large costs	Moderate costs	Negligible costs and savings	Moderate savings	Large savings	Varies	Don't know
CERTAINTY OF EVIDENCE OF REQUIRED RESOURCES	Very low	Low	Moderate	High			No included studies
COST EFFECTIVENESS	Favors the comparison	Probably favors the comparison	Does not favor either the intervention or the comparison	Probably favors the intervention	Favors the intervention	Varies	No included studies
EQUITY	Reduced	Probably reduced	Probably no impact	Probably increased	Increased	Varies	Don't know
ACCEPTABILITY	No	Probably no	Probably yes	Yes		Varies	Don't know
FEASIBILITY	No	Probably no	Probably yes	Yes		Varies	Don't know

TYPE OF RECOMMENDATION

Strong recommendation against the intervention	Conditional recommendation against the intervention	Conditional recommendation for either the intervention or the comparison	Conditional recommendation for the intervention	Strong recommendation for the intervention
0	0	0	•	0

CONCLUSIONS

Recommendation



A conditional recommendation is made for the use of antibiotics for abscesses, based on the GRADE Evidence to Decision instrument the Summary of Findings Table. The overall certainty in the evidence is low to very low. In pediatric patients, the use of antibiotics **following incision and drainage** was favorable for cure rate versus placebo. There is little evidence for or against antibiotics **following incision and drainage** (see Summary by Outcome for substantiation of recommendations).

The SSTI CPG Subcommittee discussed additional considerations using the GRADE Evidence to Decision instrument^a found in the appendix to recommend antibiotic therapy for abscess following incision and drainage at Children's Mercy based on feasibility, value, and compliance for all stakeholders.